Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

OBJECTIVES: Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) with or without a history of atherosclerotic cardiovascular disease (ASCVD) in ORAL Surveillance. METHODS: Patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Charles-Schoeman, Christina, Buch, Maya H, Dougados, Maxime, Bhatt, Deepak L, Giles, Jon T, Ytterberg, Steven R, Koch, Gary G, Vranic, Ivana, Wu, Joseph, Wang, Cunshan, Kwok, Kenneth, Menon, Sujatha, Rivas, Jose L, Yndestad, Arne, Connell, Carol A, Szekanecz, Zoltan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811099/
https://www.ncbi.nlm.nih.gov/pubmed/36137735
http://dx.doi.org/10.1136/ard-2022-222259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811099/
https://www.ncbi.nlm.nih.gov/pubmed/36137735
http://dx.doi.org/10.1136/ard-2022-222259

Ejemplares similares